AN EFFECTIVE METHOD FOR PRODUCTION OF VIRUS-LIKE PARTICLES, CARRYING HUMAN IMMUNOGLOBULIN EPITOPES
Main Article Content
Authors
A.S. Kamzina
National Center for Biotechnology, Ministry of Education and Science of the Republic of Kazakhstan, Astana, Kazakhstan
A.Zh. Baltabekova
National Center for Biotechnology, Ministry of Education and Science of the Republic of Kazakhstan, Astana, Kazakhstan
A.V. Shustov
National Center for Biotechnology, Ministry of Education and Science of the Republic of Kazakhstan, Astana, Kazakhstan
Abstract
Antigens in the form of virus-like particles (VLP) are capable of eliciting a strong humoral and cellular immune response. VLP gained popularity as a platform for the presentation of antigenic determinants of the immune system, borrowed from a huge variety of natural proteins that act as targets of the humoral response.
In this study, VLP, formed by the core protein of hepatitis B virus (HBcAg), used as a carrier of human immunoglobulin E (IgE) epitope. IgE molecules are involved in the pathological mechanism of allergies and asthma. The value of the antigens described in this work is that immunization of VLP, carrying an array of IgE epitopes, is potentially capable of eliciting antibodies that block the biological effect of IgE. Thus, VLP with IgE epitopes are promising for use in therapeutic vaccine developed for the treatment of allergic diseases and bronchial asthma.
The peptide of the constant portion of the human IgE (GETYQSRVTHPHLPRALMRSTTK) has been cloned into the main HBcAg immunodominant region using three types of linkers, which should provide the correct spatial arrangement of IgE epitope.
An efficient method of expression and purification of VLP forming recombinant protein is described.
Keywords
asthma, antibodies, IgE, antigen, recombinant, vaccine, virus-like particle
Article Details
References
Johnson J.E., Chiu W. (2000). Structure of virus and virus-like particles.Curr.Opin.Struct.Biol. 10: 229-235.
Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., Zinkernagel R.M. (1993). The influence of antigen organization on B cell responsiveness. Science 262, 1448–1451.
Whitacre D.C., Lee B.O. & Milich D.R. (2009).Use of hepadnavirus core proteins as vaccine platforms. Expert Rev Vaccines 8, 1565-1573.
Kratz P., Bottcher B., Nassal M. (1999). Native Display of Complete Foreign Protein Domains on the Surface of Hepatitis B Virus Capsids. ProcNatlAcadSci U S A. 96: 1915–1920.
Arora U., Tyagi P., Swaminathan S., Khanna N. (2012). Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2. J Nanobiotech 10:30.
Jennings G.T., Bachmann M.F. (2008). The coming of age of virus-like particle vaccines. Biol. Chem., Vol. 389, 521–536.
Holgate S., Smith N., Massanari M. & Jimenez P. (2009). Effects of omalizumab on markers of inflaмМation in patients with allergic asthma.Allergy 64, 1728-1736.
Sarinho E. & Cruz A.A. (2006). Anti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases. J Pediatr (Rio J) 82, S.127-32.
D'Amato G., Piccolo A., Salzillo A., Noschese P., D'Amato M. &Liccardi G. (2007). A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma. Recent Pat InflaмМ Allergy Drug Discov 1, 225-231.
Peng Z. (2009). Vaccines targeting IgE in the treatment of asthma and allergy. Hum Vaccin 5, 302-309.
Hunt J., Bracher M.G., Shi J., Fleury S., Dombrowicz D., Gould H.J., Sutton B.J. &Beavil A. J. (2008). Attenuation of IgE affinity for FcepsilonRI radically reduces the allergic response in vitro and in vivo. J BiolChem 283, 29882-29887.
Wang C.Y., Walfield A.M., Fang X., Hammerberg B., Ye J., Li M.L. / Synthetic IgE peptide vaccine for immunotherapy of allergy // Vaccine. – 2003. – Vol.21. – P.1580-1590.
Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning: a laboratory manual // Cold Spring Harbor: Cold Spring Harbor Laboratory Press. - 1987. – 969 p.
Billaud J.N., Peterson D., Barr M., Chen A., Sallberg M., Garduno F., Goldstein P., McDowell W., Hughes J., Jones J., Milich D. (2005). Combinatorial approach to hepadnavirus-like particle vaccine design. J Virol.; 79(21): 13656–13666.
Cheng Z. & Campbell R.E. (2009). An engineered tryptophan zipper-type peptide as a molecular recognition scaffold. J of PeptSci; 15:523-532.
Koletzki D., Zankl A., Gelderblom H.R., Meisel H., Dislers A., Borisova G., Pumpens P., Kruger D.H., Ulrich R. (1997). Mosaic hepatitis B virus core particles allow insertion of extended foreign protein segments. J Gen Virol 78, 2049-2053.